Perrigo Confirms Filing For Generic Version Of AcanyaThe Allegan generic drugmaker and store brand health products producer Perrigo Co. (NYSE: PRGO) Wednesday announced that it has filed with the U.S. Food and Drug Administration an Abbreviated New Drug Application for Clindamycin Phosphate and Benzoyl Peroxide Gel 1.2%/2.5% and has notified Dow Pharmasciences, the owner of the New Drug Application, of its filing.
Perrigo Shareholders Approve Elan AcquisitonThe generic prescription drug and store-brand health products maker Perrigo Co. (NYSE: PRGO) announced that its shareholders approved proposals related to its acuqisition of Ireland's Elan Corp. plc at a special meeting Monday.
Perrigo Company Announces Quarterly DividendPerrigo Co. (NYSE: PRGO) announced that its board declared a quarterly dividend of 9 cents per share, payable Dec. 17 to shareholders of record on Nov. 29.
Perrigo Co. Selling $2.3 Billion In Debt To Finance Elan PurchaseThe Allegan generic pharmaceutical and store-brand health products maker Perrigo Co. Ltd., which moved its corporate registration to Ireland earlier this year, said it would offer debt totaling $2.3 billion with maturities in 2016, 2018, 2023 and 2043.
Perrigo Profits, Sales RiseThe generic pharmaceutical and store-brand helath products maker Perrigo Co. (NYSE: PRGO) Thursday reported net income of $111.4 million or $1.18 a share in the first fiscal quarter ended Sept. 28, up from $105.6 million or $1.12 a share in the first fiscal quarter a year earlier. Revenue was $933.4 million, up from $769.8 million a year earlier.
Perrigo Sets Date Of Shareholder Meeting To Approve Elan AcquisitionPerrigo Co. (NYSE: PRGO) announced that it has scheduled a shareholder meeting for Monday, Nov. 18 in connection with Perrigo's proposed previously announced acquisition of Elan Corp. (NYSE: ELN).
Perrigo Announces FDA Final Approval For Generic Version Of Nitrolingual SprayPerrigo Co. (NYSE: PRGO) announced that it has received final approval for its abbreviated new drug application for nitroglycerin lingual spray, 400 mcg/spray, the generic equivalent to Nitrolingual Pumpspray.
Perrigo Company Gets FDA Approval For Generic Zyrtec For Kids, Presents At ConferencesPerrigo Co. (NYSE: PRGO) announced that it has received final approval from the U.S. Food and Drug Administration for its abbreviated new drug application for cetirizine hydrochloride oral solution USP, 1 mg/mL, bubble gum flavored, the store brand equivalent to Children's Zyrtec Allergy Syrup, 1 mg/mL, bubble gum flavored.
Perrigo Sets Records For Quarterly, Annual Sales, ProfitsThe Allegan health and beauty products maker Perrigo Co. (Nasdaq: PRGO) reported record sales and net income for the fourth fiscal quarter and fiscal year ended June 29.
Perrigo Company Announces Quarterly DividendPerrigo Co. (NYSE: PRGO) announced that its board of directors declared a quarterly dividend of 9 cents per share.
Perrigo Launching Three New ProductsThe Allegan generic drug maker will begin making two oils for dermatitis and a cancer drug.